CBio [004] a & b Tumor Immunology

Question 1

Answer 1

Question 2

Define Immunosurveillance

Answer 2

Question 3

The three possible outcomes of Immunosurveillance?

Answer 3

elimination, equilibrium, and escape

Question 4

What is RAG?

Answer 4

recombination-activating gene-2 (RAG2)

Question 5

So, what is the role of the RAG gene in normal lymphocytes?

Answer 5

Question 6

Answer 6

Question 7

What is methylcholanthrene?

Answer 7

A chemical carcinogen

Question 8

Answer 8

Question 9

Answer 9

Question 10

Other examples of co-inhibitory other than CTLA-4?

Answer 10

PD-1 and LAG-3

Question 11

PD-1 stands for?

Answer 11

programmed cell death -1

Question 12

Answer 12

Question 13

FOXP3 mutations are x-linked

Question 14

Action of TGF-Beta 1?

Answer 14

TGF-Beta 1: Inhibit proliferation and effector function of T cells Inhibit the activation of macrophages

Question 15

Action of IL-10?

Answer 15

IL-10: It is an inhibitor of activated macrophages and dendritic cells Inhibit the expression of co-stimulators and class II MHC molecules on dendritic cells and macrophages

Question 16

The T-cell ligand binding B7 on a professional antigen-presenting cell is:

A. CD28

B. CD2

C. LFA-1

D. ICAM-1

E. VCAM-1

Answer 16

A. CD28

Question 17

The main costimulatory signal for activation of resting T-cells is provided by ligation of:

• A CD28

• B Surface Ig

• C LFA-1

• D VLA-4

• E IL-2

Answer 17

• A CD28

Question 18

The normal immunological control of tumors is referred to as:

• A Immunological tolerance.

• B Immune surveillance.

• C Type III hypersensitivity.

• D Immunological silence.

• E Superantigen recognition

Answer 18

• B Immune surveillance

Question 19

Cells bearing MHC class I plus peptide are targets for specific:

• A B-cells

• B Cytotoxic T-cells

• C Th1 cells

• D Th2 cells

• E Interdigitating dendritic cells

Answer 19

• B Cytotoxic T-cells

Question 20

What is Ipilimumab?

Answer 20

anti-CTLA-4

Question 21

Question 22

What is Nivolumab?

Answer 22

PD-1 monoclonal Ab

Question 23

Tumors whom Combination therapy of Ipilimumab (a CTLA-4) and Nivolumab (a PD-1) were proven effective?

Answer 23

advanced melanoma

Question 24

Which of the following does not describe a documented mechanism of tumor-mediated immune evasion?

A. Down regulation of MHC class I

B. Secretion of TGF-Beta

C. Increase T reg

D. Antigenic variation

Answer 24

D. Antigenic variation

Question 25

Tumor editing is one of the most difficult clinically relevant problems to overcome in the course of tumor therapy. Which one of the following accounts for the mechanism of tumor editing? A. Survival of tumors with moderate expression of class II MHC molecules B. Survival of tumors with low expression of class I MHC molecules C. Survival of tumors with low expression of class II MHC molecules D. Survival of tumors with high expression of class II MHC molecules E. Survival of tumors with moderate expression of class I MHC molecules

Answer 25

B. Survival of tumors with low expression of class I MHC molecules